|

GDMT Clinical Trials

2 actively recruiting trials

▲ +1 trial since June 2026

Also known as: SGLT2 inhibitor, beta-blocker, mineralcorticoid receptor antagonist, renin-angiotensin-aldosterone system drug

Pipeline

Phase 2/3: 1

Top Sponsors

  • Università Vita-Salute San Raffaele1
  • Herlev and Gentofte Hospital1

Indications

  • Heart Disease2
  • Heart Rhythm Disorder1
  • Heart Failure With Reduced Ejection Fraction1
  • Heart Failure1

Other2 trials

Evaluating Adherence to Guideline-Directed Medical Therapy in Patients With Advanced Heart Failure
Withdrawal of Treatment for Heart Failure Patients With Recovery From Tachycardia-induced Cardiomyopathy
Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.